Walleye Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Walleye Capital’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-159	Closed	-$96K	–	2747
2021 Q4	$96K	Sell	159 -471	-75%	-$443K	﹤0.01%	1696
2021 Q3	$618	Buy	+630	New	+$788K	0.02%	691
2020 Q1	–	Sell	-70	Closed	-$180K	–	1873
2019 Q4	$180K	Buy	+70	New	+$91.2K	0.01%	1157

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's APTO Position: Q1 2022 in Review

Walleye Capital sold out of Aptose Biosciences, Inc. (APTO) in Q1 2022, closing a stake of 159 shares — an estimated $96K sold.

Walleye Capital first reported a position in APTO in Q4 2019 and held it in 3 quarters. The position peaked at $180K in Q4 2019. 52 funds tracked by Wall St. Rank hold APTO as of Q1 2022.

Walleye Capital reported no remaining Aptose Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 159 Aptose Biosciences, Inc. shares in Q1 2022, an estimated $96K.
Walleye Capital first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 3 quarters.
Walleye Capital's Aptose Biosciences, Inc. position peaked at $180K in Q4 2019.
52 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.